top of page
Green tea is a rich source of catechins, a group of flavonoids including epigallocatechin gallate (EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), and epicatechin (EC). These natural compounds have garnered significant interest due to their potential pharmacological activities. Our research is dedicated to modifying the structure of these natural catechins to enhance their therapeutic efficacy. We are particularly focused on developing novel treatments for idiopathic pulmonary fibrosis (IPF), Alzheimer's disease (AD), and nonalcoholic steatohepatitis (NASH). By optimizing the properties of catechins, we aim to create more potent and selective agents that can effectively target the pathological mechanisms underlying these diseases, offering new hope for patients affected by these challenging conditions.

Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by the scarring (fibrosis) of lung tissue, leading to a decline in lung function over time. The exact cause of IPF remains unknown, making it a challenging condition to treat. Recent research has focused on the potential use of epigallocatechin gallate (EGCG), a polyphenol found in green tea, for the treatment of IPF. EGCG has shown promise in preclinical studies for its anti-inflammatory and anti-fibrotic properties. Currently, EGCG is being evaluated in a Phase 1 clinical trial for its safety and efficacy in IPF patients. Our team is building on this research by designing new analogs of EGCG to enhance its therapeutic activity. By modifying the chemical structure of EGCG, we aim to improve its bioavailability, selectivity, and potency, making it a more effective treatment option for IPF.

NASH-Associated Liver Fibrosis

Liver fibrosis, a critical stage of nonalcoholic steatohepatitis (NASH), affects 9–15 million US adults, with ~6 million having significant fibrosis (F2–F3), driving a market projected to grow from USD 2.32B (2023) to USD 4.51B by 2032 for liver fibrosis, and USD 5.5–7.48B to USD 15–47.8B for NASH by 2027–2032. NASH, an advanced form of nonalcoholic fatty liver disease (NAFLD), risks progression to cirrhosis, liver failure, or cancer. Resmetirom (approved 2024) offers limited anti-fibrotic efficacy (25–30% fibrosis improvement), highlighting the need for targeted therapies. Epigallocatechin gallate (EGCG), a green tea antioxidant, shows preclinical anti-inflammatory and anti-fibrotic effects, but its limited bioavailability has spurred research into optimized analogs with enhanced selectivity and pharmacokinetics for NASH treatment.

Alzheimer's Disease (AD)

Alzheimer's disease is a devastating neurodegenerative disorder that presents a significant challenge in the quest for effective treatments. It is characterized by progressive memory loss and cognitive decline, severely impacting the lives of those affected. Recent research has identified epigallocatechin gallate (EGCG), a bioactive compound found in green tea, as a potential therapeutic agent for Alzheimer's disease. Studies in animal models have shown positive data, suggesting that EGCG may possess neuroprotective properties that could help slow the progression of the disease. Building on this promising foundation, our team is focused on designing new analogs of EGCG to enhance its therapeutic efficacy. Specifically, we are targeting the DYRK1A enzyme, which is believed to play a crucial role in the pathogenesis of Alzheimer's disease. By developing more potent and selective compounds that can effectively inhibit the DYRK1A enzyme, we aim to create improved treatment options that can address the underlying mechanisms of Alzheimer's disease and offer hope for those affected by this debilitating condition.
bottom of page